Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors
1. SNY stock dropped 8.52% after amlitelimab trial results disappointed investors. 2. Amlitelimab met primary endpoints but underperformed compared to Dupixent. 3. Investors doubt SNY's dermatology franchise sustainability post-Dupixent patent loss. 4. Safety profile of amlitelimab remains strong, with no new safety concerns. 5. Phase 3 trials for amlitelimab will continue through 2026, impacting future prospects.